Plain-English translation of NCT04049539 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a medication called Vyxeos—a special form of two chemotherapy drugs packaged together in tiny fat bubbles—for people with acute myeloid leukemia (a serious blood cancer) whose cancer did not respond to standard chemotherapy. The medication is given as an infusion into the vein to try to kill remaining leukemia cells. Researchers want to see if this treatment works better and is safer than repeating the original chemotherapy.
When patients receive standard chemotherapy for acute myeloid leukemia, some people's cancer doesn't go away or improve enough. These patients need another option, and this trial exists to find out whether this new medication formulation can help patients whose disease has resisted the first treatment attempt.
You likely qualify if…
You likely don't qualify if…
You will receive the study medication as an infusion into your vein on days 1 and 3 of the trial, with each infusion taking about 90 minutes. After treatment, you will have weekly follow-up visits for 60 days, then monthly visits for up to 2 years. During these visits, you will have blood tests and bone marrow checks to see how well the treatment is working and to monitor for side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States